Reapplix Achieves Major and Differentiated Wound Care Advance

article image
ARTICLE SUMMARY:

Strong clinical data and solid reimbursement bolster commercial launch of Reapplix’s personalized therapy for hard-to-heal diabetic foot ulcers.

The advanced wound care market, consisting of dressings, biologics, and devices for the treatment of difficult-to-heal chronic wounds, is challenging in several respects. First, there is the fragmentation of care (which we discussed in “Swift Medical Offers More Transparency to Wound Care,” MedTech Strategist, October 13, 2020). Second, there is very little differentiation among products—iterations revolve around some type of growth factor, a new dressing material, a new way to process or store donated tissues, vacuum pumps that are simpler or more portable—and there is scant rigorously-gathered clinical data to differentiate one from another in terms of efficacy data.

Thus, when Reapplix AS (Birkerød, Denmark and Southlake, TX) decided to enter the space with a device that CEO Graeme Brookes describes as “probably the biggest innovation in wound care since the introduction of vacuum therapy 25 years ago,” the company wanted to make sure the market understood its differentiation.

×



This article is restricted to subscribers only.

Sign in to continue reading.

Questions?

We're here to help! Please contact us at: